{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T01:38:09Z","timestamp":1792546689124,"version":"4.5.0"},"reference-count":150,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T00:00:00Z","timestamp":1612396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81770875"],"award-info":[{"award-number":["81770875"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004912","name":"Sichuan University","doi-asserted-by":"publisher","award":["2018SCUH0093"],"award-info":[{"award-number":["2018SCUH0093"]}],"id":[{"id":"10.13039\/501100004912","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The complex crosstalk between the immune and the skeletal systems plays an indispensable role in the maintenance of skeletal homeostasis. Various cytokines are involved, including interleukin (IL)-17A. A variety of immune and inflammatory cells produces IL-17A, especially Th17 cells, a subtype of CD4<jats:sup>+<\/jats:sup>T cells. IL-17A orchestrates diverse inflammatory and immune processes. IL-17A induces direct and indirect effects on osteoclasts. The dual role of IL-17A on osteoclasts partly depends on its concentrations and interactions with other factors. Interestingly, IL-17A exerts a dual role in osteoblasts<jats:italic>in\u00a0vitro<\/jats:italic>. IL-17A is a bone-destroying cytokine in numerous immune-mediated bone diseases including postmenopausal osteoporosis (PMOP), rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondylarthritis (axSpA). This review will summarize and discuss the pathophysiological roles of IL-17A on the skeletal system and its potential strategies for application in immune-mediated bone diseases.<\/jats:p>","DOI":"10.3389\/fimmu.2020.625034","type":"journal-article","created":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T05:55:01Z","timestamp":1612418101000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":62,"title":["Interleukin-17A Interweaves the Skeletal and Immune Systems"],"prefix":"10.3389","volume":"11","author":[{"given":"Mengjia","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xijie","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,2,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/978-981-13-9367-9_5","article-title":"Structural Insights into the Interleukin-17 Family Cytokines and Their Receptors","volume":"1172","author":"Liu","year":"2019","journal-title":"Adv Exp Med Biol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1189\/jlb.71.1.1","article-title":"IL-17: prototype member of an emerging cytokine family","volume":"71","author":"Aggarwal","year":"2002","journal-title":"J leukocyte Biol"},{"key":"B3","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.150.12.5445","article-title":"CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene","volume":"150","author":"Rouvier","year":"1993","journal-title":"J Immunol"},{"key":"B4","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.155.12.5483","article-title":"Human IL-17: a novel cytokine derived from T cells","volume":"155","author":"Yao","year":"1995","journal-title":"J Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1084\/jem.183.6.2593","article-title":"T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines","volume":"183","author":"Fossiez","year":"1996","journal-title":"J Exp Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.micinf.2009.04.003","article-title":"IL-17 and Th17 cells in human inflammatory diseases","volume":"11","author":"Miossec","year":"2009","journal-title":"Microbes Infect"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/art.38376","article-title":"Interleukin-17+CD8+ T Cells Are Enriched in the Joints of Patients With Psoriatic Arthritis and Correlate With Disease Activity and Joint Damage Progression","volume":"66","author":"Menon","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41467-018-07911-6","article-title":"RORgammat inhibition selectively targets IL-17 producing iNKT and gammadelta-T cells enriched in Spondyloarthritis patients","volume":"10","author":"Venken","year":"2019","journal-title":"Nat Commun"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-019-09095-7","article-title":"Characterization of IL-17-producing Treg cells in type 2 diabetes patients","volume":"67","author":"Zhu","year":"2019","journal-title":"Immunologic Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/nature14282","article-title":"IL-17-producing \u03b3\u03b4 T cells and neutrophils conspire to promote breast cancer metastasis","volume":"522","author":"Coffelt","year":"2015","journal-title":"Nature"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20091509","article-title":"Human NKp44+IL-22+ cells and LTi-like cells constitute a stable RORC+ lineage distinct from conventional natural killer cells","volume":"207","author":"Crellin","year":"2010","journal-title":"J Exp Med"},{"key":"B12","article-title":"Evidence of IL-17 producing innate lymphoid cells in peripheral blood from patients with enteropathic spondyloarthritis","volume":"34","author":"Triggianese","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"B13","article-title":"Increased expression of interleukin-17 is associated with macrophages in chronic immune thrombocytopenia","volume":"11","author":"Okamoto","year":"2018","journal-title":"Int J Clin Exp Pathol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1172\/JCI38702","article-title":"IL-17 produced by neutrophils regulates IFN-gamma-mediated neutrophil migration in mouse kidney ischemia-reperfusion injury","volume":"120","author":"Li","year":"2010","journal-title":"J Clin Invest"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0903566","article-title":"Mast cells express IL-17A in rheumatoid arthritis synovium","volume":"184","author":"Hueber","year":"2010","journal-title":"J Immunol (Baltimore Md 1950)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20080588","article-title":"IL-17 produced by Paneth cells drives TNF-induced shock","volume":"205","author":"Takahashi","year":"2008","journal-title":"J Exp Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/art.22794","article-title":"Prostaglandin E2 exacerbates collagen-induced arthritis in mice through the inflammatory interleukin-23\/interleukin-17 axis","volume":"56","author":"Sheibanie","year":"2007","journal-title":"Arthritis Rheum"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1038\/s41467-019-09883-7","article-title":"IL-1\u03b2, IL-23, and TGF-\u03b2 drive plasticity of human ILC2s towards IL-17-producing ILCs in nasal inflammation","volume":"10","author":"Golebski","year":"2019","journal-title":"Nat Commun"},{"key":"B19","doi-asserted-by":"publisher","first-page":"R143","DOI":"10.1186\/ar4326","article-title":"Interferon alpha inhibits antigen-specific production of proinflammatory cytokines and enhances antigen-specific transforming growth factor beta production in antigen-induced arthritis","volume":"15","author":"Chalise","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02107","article-title":"Characteristic Pattern of IL-17RA, IL-17RB, and IL-17RC in Monocytes\/Macrophages and Mast Cells From Patients With Bullous Pemphigoid","volume":"10","author":"Nesmond","year":"2019","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.1.655","article-title":"IL-17RA and IL-17RC receptors are essential for IL-17A-induced ELR+ CXC chemokine expression in synoviocytes and are overexpressed in rheumatoid blood","volume":"180","author":"Zrioual","year":"2008","journal-title":"J Immunol (Baltimore Md 1950)"},{"key":"B22","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.cyto.2007.11.013","article-title":"Structure-function relationships in the IL-17 receptor: implications for signal transduction and therapy","volume":"41","author":"Shen","year":"2008","journal-title":"Cytokine"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.2174\/0929866522666150520145554","article-title":"An Overview of Interleukin-17A and Interleukin-17 Receptor A Structure, Interaction and Signaling","volume":"22","author":"Krstic","year":"2015","journal-title":"Protein Pept Lett"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1038\/ncomms2880","article-title":"Crystal structures of interleukin 17A and its complex with IL-17 receptor A","volume":"4","author":"Liu","year":"2013","journal-title":"Nat Commun"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/nri2586","article-title":"Structure and signalling in the IL-17 receptor family","volume":"9","author":"Gaffen","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/nri.2015.2","article-title":"IL-17 receptor composition","volume":"16","author":"Gaffen","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-019-0514-y","article-title":"IL-17 receptor-based signaling and implications for disease","volume":"20","author":"Li","year":"2019","journal-title":"Nat Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201242605","article-title":"Immunity to infection in IL-17-deficient mice and humans","volume":"42","author":"Cypowyj","year":"2012","journal-title":"Eur J Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/prd.12083","article-title":"Basic biology and role of interleukin-17 in immunity and inflammation","volume":"69","author":"Zenobia","year":"2015","journal-title":"Periodontol 2000"},{"key":"B30","doi-asserted-by":"publisher","first-page":"3880","DOI":"10.3390\/ijms19123880","article-title":"The Interleukin-17 Family of Cytokines in Breast Cancer","volume":"19","author":"Fabre","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/8494079","article-title":"The Role of Interleukin-17 in Lung Cancer","volume":"2016","author":"Wu","year":"2016","journal-title":"Mediators Inflammation"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2017.07.009","article-title":"Effects of Interleukin 17 on the cardiovascular system","volume":"16","author":"Robert","year":"2017","journal-title":"Autoimmun Rev"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.4103\/0301-4738.194339","article-title":"Roles of interleukin-17 in uveitis","volume":"64","author":"Guedes","year":"2016","journal-title":"Indian J Ophthalmol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"R29","DOI":"10.1186\/ar2936","article-title":"Interleukin-17A upregulates receptor activator of NF-kappaB on osteoclast precursors","volume":"12","author":"Adamopoulos","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2018.02.164","article-title":"IL-17A regulates the autophagic activity of osteoclast precursors through RANKL-JNK1 signaling during osteoclastogenesis in vitro","volume":"497","author":"Ke","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2018.12.029","article-title":"IL-17A modulates osteoclast precursors\u2019 apoptosis through autophagy-TRAF3 signaling during osteoclastogenesis","volume":"508","author":"Xue","year":"2019","journal-title":"Biochem Biophys Res Commun"},{"key":"B37","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.biochi.2009.12.011","article-title":"IL-17A suppresses the expression of bone resorption-related proteinases and osteoclast differentiation via IL-17RA or IL-17RC receptors in RAW264.7 cells","volume":"92","author":"Kitami","year":"2010","journal-title":"Biochimie"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0044552","article-title":"Estrogen deficiency induces the differentiation of IL-17 secreting Th17 cells: a new candidate in the pathogenesis of osteoporosis","volume":"7","author":"Tyagi","year":"2012","journal-title":"PloS One"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2009.74","article-title":"IL-17 stimulates the proliferation and differentiation of human mesenchymal stem cells: implications for bone remodeling","volume":"16","author":"Huang","year":"2009","journal-title":"Cell Death Differ"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.24165","article-title":"IL-17 mediates estrogen-deficient osteoporosis in an Act1-dependent manner","volume":"113","author":"DeSelm","year":"2012","journal-title":"J\u00a0Cell Biochem"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3109\/03008200903456942","article-title":"Compressive force stimulates the gene expression of IL-17s and their receptors in MC3T3-E1 cells","volume":"51","author":"Zhang","year":"2010","journal-title":"Connective Tissue Res"},{"key":"B42","doi-asserted-by":"publisher","first-page":"8","DOI":"10.33160\/yam.2018.03.002","article-title":"Resolvin E1 Inhibits Osteoclastogenesis and Bone Resorption by Suppressing IL-17-induced RANKL Expression in Osteoblasts and RANKL-induced Osteoclast Differentiation","volume":"61","author":"Funaki","year":"2018","journal-title":"Yonago Acta Med"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.intimp.2018.02.002","article-title":"The positive effects of secreting cytokines IL-17 and IFN-\u03b3 on the early-stage differentiation and negative effects on the calcification of primary osteoblasts in vitro","volume":"57","author":"Wang","year":"2018","journal-title":"Int Immunopharmacol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2020.02.054","article-title":"IL-17 promotes osteoblast differentiation, bone regeneration, and remodeling in mice","volume":"55","author":"Kim","year":"2020","journal-title":"Biochem Biophys Res Commun"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3600","article-title":"IL-17 Receptor Signaling in Osteoblasts\/Osteocytes Mediates PTH-Induced Bone Loss and Enhances Osteocytic RANKL Production","volume":"34","author":"Li","year":"2019","journal-title":"J Bone mineral Res Off J Am Soc Bone Mineral Res"},{"key":"B46","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.biochi.2010.10.001","article-title":"Interleukin-17A induces cathepsin K and MMP-9 expression in osteoclasts via celecoxib-blocked prostaglandin E2 in osteoblasts","volume":"93","author":"Zhang","year":"2011","journal-title":"Biochimie"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/s8756-3282(00)00457-9","article-title":"Effect of interleukin-17 on nitric oxide production and osteoclastic bone resorption: is there dependency on nuclear factor-kappaB and receptor activator of nuclear factor kappaB (RANK)\/RANK ligand signaling","volume":"28","author":"Van Bezooijen","year":"2001","journal-title":"Bone"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.1999.14.9.1513","article-title":"Interleukin-17: A new bone acting cytokine in vitro","volume":"14","author":"Van bezooijen","year":"1999","journal-title":"J Bone mineral Res Off J Am Soc Bone Mineral Res"},{"key":"B49","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.bone.2017.04.003","article-title":"Shear stress inhibits IL-17A-mediated induction of osteoclastogenesis via osteocyte pathways","volume":"101","author":"Liao","year":"2017","journal-title":"Bone"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1002\/art.37762","article-title":"Interleukin-17A stimulates granulocyte-macrophage colony-stimulating factor release by murine osteoblasts in the presence of 1,25-dihydroxyvitamin D(3) and inhibits murine osteoclast development in vitro","volume":"65","author":"Balani","year":"2013","journal-title":"Arthritis Rheum"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2011.08.003","article-title":"TNFalpha inhibits the development of osteoclasts through osteoblast-derived GM-CSF","volume":"49","author":"Atanga","year":"2011","journal-title":"Bone"},{"key":"B52","doi-asserted-by":"publisher","first-page":"330ra37","DOI":"10.1126\/scitranslmed.aad8996","article-title":"Chronic skin inflammation leads to bone loss by IL-17-mediated inhibition of Wnt signaling in osteoblasts","volume":"8","author":"Ulu\u00e7kan","year":"2016","journal-title":"Sci Transl Med"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1634\/stemcells.2005-0156","article-title":"Interleukin-17A: a T-cell-derived growth factor for murine and human mesenchymal stem cells","volume":"24","author":"Huang","year":"2006","journal-title":"Stem Cells (Dayton Ohio)"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2017.7315","article-title":"AKT2 is involved in the IL\u221217A\u2212mediated promotion of differentiation and calcification of murine preosteoblastic MC3T3\u2212E1 cells","volume":"16","author":"Tan","year":"2017","journal-title":"Mol Med Rep"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.29323","article-title":"IL-17 alters the mesenchymal stem cell niche towards osteogenesis in cooperation with osteocytes","volume":"235","author":"Liao","year":"2020","journal-title":"J Cell Physiol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.archoralbio.2014.05.009","article-title":"IL-17 inhibits osteoblast differentiation and bone regeneration in rat","volume":"59","author":"Kim","year":"2014","journal-title":"Arch Oral Biol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/5950395","article-title":"Different Modulatory Effects of IL-17, IL-22, and IL-23 on Osteoblast Differentiation","volume":"2017","author":"Zhang","year":"2017","journal-title":"Mediators Inflammation"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2017.09.010","article-title":"Combination of PTH (1-34) with anti-IL17 prevents bone loss by inhibiting IL-17\/N-cadherin mediated disruption of PTHR1\/LRP-6 interaction","volume":"105","author":"Mansoori","year":"2017","journal-title":"Bone"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-018-1582-3","article-title":"IL-17A induces osteoblast differentiation by activating JAK2\/STAT3 in ankylosing spondylitis","volume":"20","author":"Jo","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2016.01.010","article-title":"Proinflammatory T cells and IL-17 stimulate osteoblast differentiation","volume":"84","author":"Croes","year":"2016","journal-title":"Bone"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00425","article-title":"Effects of Interleukin-17A on Osteogenic Differentiation of Isolated Human Mesenchymal Stem Cells","author":"Osta","year":"2014","journal-title":"Front Immunol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2009.03.008","article-title":"Interleukin-17A inhibits adipocyte differentiation in human mesenchymal stem cells and regulates pro-inflammatory responses in adipocytes","volume":"77","author":"Shin","year":"2009","journal-title":"Biochem Pharmacol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.12659\/msm.903027","article-title":"IL-17A Inhibits Osteogenic Differentiation of Bone Mesenchymal Stem Cells via Wnt Signaling Pathway","volume":"23","author":"Wang","year":"2017","journal-title":"Med Sci Monit Int Med J Exp Clin Res"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200939670","article-title":"A bone-protective role for IL-17 receptor signaling in ovariectomy-induced bone loss","volume":"39","author":"Goswami","year":"2009","journal-title":"Eur J Immunol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.cmet.2015.09.012","article-title":"IL-17A Is Increased in Humans with Primary Hyperparathyroidism and Mediates PTH-Induced Bone Loss in Mice","volume":"22","author":"Li","year":"2015","journal-title":"Cell Metab"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20061775","article-title":"Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction","volume":"203","author":"Sato","year":"2006","journal-title":"J Exp Med"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32112-3","article-title":"Osteoporosis","volume":"393","author":"Compston","year":"2019","journal-title":"Lancet"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1513724","article-title":"Clinical Practice. Postmenopausal Osteoporosis","volume":"374","author":"Black","year":"2016","journal-title":"New Engl J Med"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.5180","article-title":"Immune regulation of osteoclast function in postmenopausal osteoporosis: a critical interdisciplinary perspective","volume":"9","author":"Zhao","year":"2012","journal-title":"Int J Med Sci"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/575936","article-title":"Postmenopausal osteoporosis: the role of immune system cells","volume":"2013","author":"Faienza","year":"2013","journal-title":"Clin Dev Immunol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.bone.2008.02.017","article-title":"Estrogen deficiency increases osteoclastogenesis up-regulating T cells activity: a key mechanism in osteoporosis","volume":"43","author":"D\u2019Amelio","year":"2008","journal-title":"Bone"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.01530","article-title":"Tetrandrine Prevents Bone Loss in Ovariectomized Mice by Inhibiting RANKL-Induced Osteoclastogenesis","volume":"10","author":"Zhong","year":"2020","journal-title":"Front Pharmacol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2012.06.100","article-title":"TNF-\u03b1 mediates the stimulation of sclerostin expression in an estrogen-deficient condition","volume":"424","author":"Kim","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2015.07.010","article-title":"The roles of interferons in osteoclasts and osteoclastogenesis","volume":"83","author":"Xiong","year":"2016","journal-title":"Joint bone Spine Rev du rhumatisme"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0404888101","article-title":"Estrogen prevents bone loss through transforming growth factor beta signaling in T cells","volume":"101","author":"Gao","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02666","article-title":"Commentary: Circulatory pattern of cytokines, adipokines and bone markers in postmenopausal women with low BMD","volume":"10","author":"Mannucci","year":"2019","journal-title":"Front Immunol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1159\/000443531","article-title":"Upregulated Cellular Expression of IL-17 by CD4+ T-Cells in Osteoporotic Postmenopausal Women","volume":"68","author":"Zhao","year":"2016","journal-title":"Ann Nutr Metab"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3109\/09513590.2014.975683","article-title":"Changes of serum cytokines-related Th1\/Th2\/Th17 concentration in patients with postmenopausal osteoporosis","volume":"31","author":"Zhang","year":"2015","journal-title":"Gynecol Endocrinol Off J Int Soc Gynecol Endocrinol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-013-2548-6","article-title":"IL-17A-mediated sRANK ligand elevation involved in postmenopausal osteoporosis","volume":"25","author":"Moln\u00e1r","year":"2014","journal-title":"Osteoporosis Int"},{"key":"B80","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.bone.2018.01.027","article-title":"Efficacy of anti-IL-23 monotherapy versus combination therapy with anti-IL-17 in estrogen deficiency induced bone loss conditions","volume":"110","author":"Shukla","year":"2018","journal-title":"Bone"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.2228","article-title":"Enhanced immunoprotective effects by anti-IL-17 antibody translates to improved skeletal parameters under estrogen deficiency compared with anti-RANKL and anti-TNF-alpha antibodies","volume":"29","author":"Tyagi","year":"2014","journal-title":"J Bone mineral Res Off J Am Soc Bone Mineral Res"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"Lancet (London England)"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199905)42:5<963::aid-anr15>3.0.co;2-e","article-title":"Human interleukin-17: A T cell-derived proinflammatory cytokine produced by the rheumatoid synovium","volume":"42","author":"Chabaud","year":"1999","journal-title":"Arthritis Rheum"},{"key":"B84","article-title":"Pathologic finding of increased expression of interleukin-17 in the synovial tissue of rheumatoid arthritis patients","volume":"6","author":"Li","year":"2013","journal-title":"Int J Clin Exp Pathol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.164.5.2832","article-title":"High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism","volume":"164","author":"Ziolkowska","year":"2000","journal-title":"J Immunol (Baltimore Md 1950)"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1002\/art.21749","article-title":"Synovial membrane cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two-year prospective study (the DAMAGE study cohort)","volume":"54","author":"Kirkham","year":"2006","journal-title":"Arthritis Rheum"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/3109135","article-title":"The Relationship of Cytokines IL-13 and IL-17 with Autoantibodies Profile in Early Rheumatoid Arthritis","volume":"2016","author":"Silo\u015fi","year":"2016","journal-title":"J Immunol Res"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1080\/15321819.2019.1649695","article-title":"Elevated levels of inflammatory markers in women with rheumatoid arthritis","volume":"40","author":"Costa","year":"2019","journal-title":"J Immunoassay Immunochem"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.4155\/bio-2016-0207","article-title":"Characterization of IL-17AA and IL-17FF in rheumatoid arthritis and multiple sclerosis","volume":"8","author":"Schofield","year":"2016","journal-title":"Bioanalysis"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1136\/postgradmedj-2016-134637","article-title":"Associations between circulating IL-17 levels and rheumatoid arthritis and between IL-17 gene polymorphisms and disease susceptibility: a meta-analysis","author":"Lee","year":"1102","journal-title":"Postgraduate Med J"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1186\/ar1470","article-title":"Increased interleukin-17 production via a phosphoinositide 3-kinase\/Akt and nuclear factor kappaB-dependent pathway in patients with rheumatoid arthritis","volume":"7","author":"Kim","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"B92","first-page":"73","article-title":"IL-17 patterns in synovium, serum and synovial fluid from treatment-na\u00efve, early rheumatoid arthritis patients","volume":"53","author":"Ro\u015fu","year":"2012","journal-title":"Romanian J Morphol Embryol = Rev roumaine morphologie embryologie"},{"key":"B93","first-page":"19","article-title":"Correlation between Relative Expression of IL 17 and PERP in Rheumatoid Arthritis Patients and Disease Activity","volume":"26","author":"El-Maghraby","year":"2019","journal-title":"Egyptian J Immunol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1002\/art.27186","article-title":"Up-regulation of cytokines and chemokines predates the onset of rheumatoid arthritis","volume":"62","author":"Kokkonen","year":"2010","journal-title":"Arthritis Rheum"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1186\/ar1733","article-title":"Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin","volume":"7","author":"Raza","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"B96","article-title":"Correlation between rheumatoid arthritis and immunological changes in a rheumatoid arthritis rat model","volume":"32","author":"Wu","year":"2018","journal-title":"J Biol Regul Homeostatic Agents"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003370","article-title":"Th17 cells, not IL-17+ gammadelta T cells, drive arthritic bone destruction in mice and humans","volume":"186","author":"Pollinger","year":"2011","journal-title":"J Immunol (Baltimore Md 1950)"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1007\/bf02684010","article-title":"Overexpression of IL-17 in the knee joint of collagen type II immunized mice promotes collagen arthritis and aggravates joint destruction","volume":"51","author":"Lubberts","year":"2002","journal-title":"Inflammation Res Off J Eur Histamine Res Soc [et al]"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1002\/art.10173","article-title":"Reduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with interleukin-17 receptor IgG1 Fc fusion protein","volume":"46","author":"Bush","year":"2002","journal-title":"Arthritis Rheum"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.167.2.1004","article-title":"IL-1-independent role of IL-17 in synovial inflammation and joint destruction during collagen-induced arthritis","volume":"167","author":"Lubberts","year":"2001","journal-title":"J Immunol (Baltimore Md 1950)"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.170.5.2655","article-title":"IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B ligand\/osteoprotegerin balance","volume":"170","author":"Lubberts","year":"2003","journal-title":"J Immunol (Baltimore Md 1950)"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1002\/art.20001","article-title":"Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion","volume":"50","author":"Lubberts","year":"2004","journal-title":"Arthritis Rheumatic"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1801436","article-title":"Combined Blockade of TNF-\u03b1 and IL-17A Alleviates Progression of Collagen-Induced Arthritis without Causing Serious Infections in Mice","volume":"202","author":"Shen","year":"2019","journal-title":"J Immunol"},{"key":"B104","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.intimp.2012.12.010","article-title":"Synergistic effects of interleukin-1\u03b2 and interleukin-17A antibodies on collagen-induced arthritis mouse model","volume":"15","author":"Zhang","year":"2013","journal-title":"Int Immunopharmacol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2014.04.018","article-title":"Therapeutic efficacy of three bispecific antibodies on collagen-induced arthritis mouse model","volume":"21","author":"Li","year":"2014","journal-title":"Int Immunopharmacol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.171.11.6173","article-title":"Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice","volume":"171","author":"Nakae","year":"2003","journal-title":"J Immunol (Baltimore Md 1950)"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.3109\/08916934.2010.517815","article-title":"Anti-IL-17A therapy protects against bone erosion in experimental models of rheumatoid arthritis","volume":"44","author":"Chao","year":"2011","journal-title":"Autoimmunity"},{"key":"B108","doi-asserted-by":"publisher","first-page":"R164","DOI":"10.1186\/ar4347","article-title":"A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis","volume":"15","author":"Martin","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1002\/art.38617","article-title":"A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors","volume":"66","author":"Genovese","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214943","article-title":"Efficacy and safety of bimekizumab as add-on therapy for rheumatoid arthritis in patients with inadequate response to certolizumab pegol: a proof-of-concept study","volume":"78","author":"Glatt","year":"2019","journal-title":"Ann Rheumatic Dis"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.130637","article-title":"One-year Efficacy and Safety Results of Secukinumab in Patients With Rheumatoid Arthritis: Phase II, Dose-finding, Double-blind, Randomized, Placebo-controlled Study","volume":"41","author":"Genovese","year":"2014","journal-title":"J Rheumatol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1002\/art.40070","article-title":"Secukinumab in Active Rheumatoid Arthritis: A Phase III Randomized, Double-Blind, Active Comparator- and Placebo-Controlled Study","volume":"69","author":"Blanco","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-019-04595-1","article-title":"Efficacy and safety of secukinumab in active rheumatoid arthritis with an inadequate response to tumor necrosis factor inhibitors: a meta-analysis of phase III randomized controlled trials","volume":"38","author":"Huang","year":"2019","journal-title":"Clin Rheumatol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1080\/03009742.2017.1390605","article-title":"Secukinumab after anti-tumour necrosis factor-\u03b1 therapy: a phase III study in active rheumatoid arthritis","volume":"47","author":"Dokoupilov\u00e1","year":"2018","journal-title":"Scand J Rheumatol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-1833","article-title":"Current concepts in psoriatic arthritis: pathogenesis and management","volume":"94","author":"de Vlam","year":"2014","journal-title":"Acta Dermato Venereologica"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic Arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"New Engl J Med"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)30830-4","article-title":"The pathogenesis of psoriatic arthritis","volume":"391","author":"Veale","year":"2018","journal-title":"Lancet (London England)"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2010.09992.x","article-title":"Interleukin (IL)-22, IL-17, IL-23, IL-8, vascular endothelial growth factor and tumour necrosis factor-\u03b1 levels in patients with psoriasis before, during and after psoralen-ultraviolet A and narrowband ultraviolet B therapy","volume":"163","author":"Coimbra","year":"2010","journal-title":"Br J Dermatol"},{"key":"B119","doi-asserted-by":"publisher","first-page":"R136","DOI":"10.1186\/ar4317","article-title":"Th17 and Th22 cells in psoriatic arthritis and psoriasis","volume":"15","author":"Benham","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1002\/art.23655","article-title":"Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides","volume":"58","author":"Jandus","year":"2008","journal-title":"Arthritis Rheum"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1002\/art.39261","article-title":"Brief report: enrichment of activated group 3 innate lymphoid cells in psoriatic arthritis synovial fluid","volume":"67","author":"Leijten","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201646774","article-title":"Psoriatic cutaneous inflammation promotes human monocyte differentiation into active osteoclasts, facilitating bone damage","volume":"47","author":"Raimondo","year":"2017","journal-title":"Eur J Immunol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(15)61134-5","article-title":"Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"McInnes","year":"2015","journal-title":"Lancet (London England)"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212687","article-title":"Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study","volume":"77","author":"Mease","year":"2018","journal-title":"Ann Rheumatic Dis"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa313","article-title":"Effect of biologics on radiographic progression of peripheral joint in patients with psoriatic arthritis: meta-analysis","volume":"59","author":"Wu","year":"2020","journal-title":"Rheumatol (Oxford England)"},{"key":"B126","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13075-018-1653-5","article-title":"Resolution of synovitis and arrest of catabolic and anabolic bone changes in patients with psoriatic arthritis by IL-17A blockade with secukinumab: results from the prospective PSARTROS study","volume":"20","author":"Kampylafka","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412679","article-title":"Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis","volume":"373","author":"Mease","year":"2015","journal-title":"New Engl J Med"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(17)31429-0","article-title":"Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial","volume":"389","author":"Nash","year":"2017","journal-title":"Lancet (London England)"},{"key":"B129","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","article-title":"Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1","volume":"76","author":"Mease","year":"2017","journal-title":"Ann Rheumatic Dis"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216835","article-title":"Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials","volume":"80","author":"Mease","year":"2020","journal-title":"Ann Rheumatic Dis"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.7573\/dic.212570","article-title":"Brodalumab in psoriasis: evidence to date and clinical potential","volume":"8","author":"Foulkes","year":"2019","journal-title":"Drugs context"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(19)33161-7","article-title":"Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial","volume":"395","author":"Ritchlin","year":"2020","journal-title":"Lancet (London England)"},{"key":"B133","doi-asserted-by":"publisher","first-page":"15013","DOI":"10.1038\/nrdp.2015.13","article-title":"Axial spondyloarthritis","volume":"1","author":"Sieper","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2017.56","article-title":"Pathogenesis of ankylosing spondylitis - recent advances and future directions","volume":"13","author":"Ranganathan","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-018-0044-2","article-title":"IL-17 in the immunopathogenesis of spondyloarthritis","volume":"14","author":"Taams","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu382","article-title":"IL-17-producing CD4+ T cells are increased in early, active axial spondyloarthritis including patients without imaging abnormalities","volume":"54","author":"Jansen","year":"2015","journal-title":"Rheumatol (Oxford England)"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1002\/art.24568","article-title":"Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis","volume":"60","author":"Shen","year":"2009","journal-title":"Arthritis Rheum"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1002\/art.33507","article-title":"Enrichment of circulating interleukin-17-secreting interleukin-23 receptor-positive \u03b3\/\u03b4 T cells in patients with active ankylosing spondylitis","volume":"64","author":"Kenna","year":"2012","journal-title":"Arthritis Rheum"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-010-1647-4","article-title":"Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis","volume":"30","author":"Mei","year":"2011","journal-title":"Clin Rheumatol"},{"key":"B140","article-title":"Elevated serum levels of IL-6 and IL-17 may associate with the development of ankylosing spondylitis","volume":"8","author":"Liu","year":"2015","journal-title":"Int J Clin Exp Med"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1002\/art.40770","article-title":"Interleukin-17A Inhibition Diminishes Inflammation and New Bone Formation in Experimental Spondyloarthritis","volume":"71","author":"van Tok","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"B142","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1186\/s13075-017-1490-y","article-title":"Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3","volume":"19","author":"Pavelka","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"B143","article-title":"Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the Phase 3 MEASURE 1 trial","volume":"36","author":"Baraliakos","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"B144","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s11926-019-0818-9","article-title":"The Effect of TNF Inhibition on Bone Density and Fracture Risk and of IL17 Inhibition on Radiographic Progression and Bone Density in Patients with Axial Spondyloarthritis: a Systematic Literature Review","volume":"21","author":"Ashany","year":"2019","journal-title":"Curr Rheumatol Rep"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1002\/art.41477","article-title":"Secukinumab improves signs and symptoms of non-radiographic axial spondyloarthritis: primary results of a randomized controlled phase III study","volume":"73","author":"Deodhar","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)31946-9","article-title":"Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial","volume":"392","author":"van der Heijde","year":"2018","journal-title":"Lancet (London England)"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216118","article-title":"Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)","volume":"79","author":"Dougados","year":"2020","journal-title":"Ann Rheumatic Dis"},{"key":"B148","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/s0140-6736(19)32971-x","article-title":"Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet (London England)"},{"key":"B149","first-page":"27","article-title":"Primary efficacy of netakimab, a novel interleukin-17 inhibitor, in the treatment of active ankylosing spondylitis in adults","volume":"38","author":"Erdes","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"B150","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1136\/annrheumdis-2020-216980","article-title":"Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study","volume":"79","author":"van der Heijde","year":"2020","journal-title":"Ann Rheumatic Dis"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.625034\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T07:27:00Z","timestamp":1697786820000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2020.625034\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,4]]},"references-count":150,"alternative-id":["10.3389\/fimmu.2020.625034"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.625034","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,4]]},"article-number":"625034"}}